Elevated PSA? You May Not Need a Prostate Biopsy

​​​While Prostate Specific Antigen (PSA) is currently the most used screening test for prostate cancer, it is widely recognized that PSA results can indicate the possibility of prostate cancer when none is present. Studies have shown that approximately 70% of men with an elevated PSA who have a biopsy do not have cancer.(1)

The Prostate Health Index (​phi ) Can Help Reduce Unnecessary Biopsies

The Prostate Health Index is an FDA approved blood test that can help differentiate prostate cancer from benign conditions in men with elevated PSA. ​The Prostate Health Index utilizes three different PSA markers (PSA, freePSA, and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels and can help men and their physicians decide if a prostate biopsy is indicated. 2-5 The Prostate Health Index is now available through the AVRT telehealth program. AVRT™ is a comprehensive telehealth program that uses advanced diagnostics, evidence-based clinical protocols and online physician supervision to help patients stay well and reduce the risk of developing cancer and other chronic diseases.

Am I a Candidate?

Male patients may be a candidate for the Prostate Index Test if they are age 50 years and older with an elevated PSA between 4ng/ml and 10ng/ml. Peer-reviewed published studies support the use of Prostate Health Index in men with total PSA values as low as 2 ng/ml. 1-4 The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) Guideline for Prostate Cancer Early Detection as a blood test to improve specificity for prostate cancer detection. 6

How it Works

Complete your online intake form to determine your eligibility for testing.

After you make your secure online payment for your test, we’ll schedule testing at a lab near your or arrange for a mobile phlebotomist to come to your home.

When we receive your test results, we’ll reach out to schedule a time to review them with a telehealth physician.

Contact Us to get Started!

Fill out the form below and an AVRT representative will reach out to you soon to answer any questions you may have.

By submitting this form, you are confirming that you would like to receive information on the AVRT telehealth program. You can unsubscribe at any time.
This field is for validation purposes and should be left unchanged.

Additional Testing for Early Cancer Detection

In addition to the AVRT panel, we offer advanced blood tests for early cancer detection*. These tests are offered by StageZero Life Sciences, a CLIA Certified, CAP Accredited High Complexity Laboratory in Richmond, VA.  Be sure to ask your case manager about any of the tests below. Pricing and availability vary.


Aristotle is a blood test that uses advanced mRNA technology to identify the molecular signatures of multiple cancers from a single blood draw. (7)

Learn More


ColonSentry is a blood test that uses advanced mRNA gene expression technology to help identify Colorectal Cancer (CRC) early when it’s most treatable. (8)

Learn More


BreastSentry is a blood test that can help identify if a woman has an increased risk for developing breast cancer. (9)

Learn More


The Prostate Health Index is an FDA approved blood test that can help men with elevated PSA differentiate benign prostate conditions from prostate cancer. (1-3)

Learn More

* These tests are priced separately and not included in the cost of the AVRT Panel & Physician Consult.


  1. Biddle C, Brasel A, Underwood W 3rd, et al. Experiences of Uncertainty in Men With an Elevated PSA. Am J Mens Health. 2016;11(1):24-34.
  2. Catalona WJ, Partin AW, Sanda MG, et al. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. The Journal of Urology. 2011;185(5):1650-1655.
  3. Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of Urology. 2015;193(4):1163-1169
  4. Huang YQ, Sun T, Zhong WD, et al. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol 2014;2(4):343-350
  5. Lepor A, Catalona WJ, Loeb S. The Prostate Health Index: Its Utility In Prostate Cancer Detection. The Urologic Clinics of North America. 2016;43(1):1-6.
  6. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 2.2018 – April 5, 2018
  7. Dempsey A, Chao S, Stamatiou D, et al., Aristotle: A single blood test for pan-cancer screening. Journal of Clinical Oncology. 2020; 38:15_suppl, e15037-e15037
  8. Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006 Mar;147(3):126-32.
  9. Melander O, Belting M, Manjer J, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer. Cancer Epidemiology and Prevention Biomarkers 23.8 (2014): 1672-1676.
Aristotle, ColonSentry, & BreastSentry tests were developed, and their performance characteristics determined by Stage Zero Life Sciences, Inc.; they have not been cleared or approved by the US Food and Drug Administration. These tests were performed in a CLIA certified laboratory and are intended for clinical purposes. The Aristotle, Prostate Health Index, ColonSentry, & BreastSentry tests must be ordered by and used only in consultation with a healthcare provider.